Tribenoside

Tribenoside
Clinical data
Other names	(3R,4R,5R)-4-(Benzyloxy)-5-[1,2-bis(benzyloxy)ethyl]-2-ethoxyoxolan-3-ol
AHFS/Drugs.com	International Drug Names
ATC code	C05AX05 (WHO) C05CX01 (WHO);
Identifiers
	IUPAC name Ethyl 3,5,6-tri-O-benzyl-D-glucofuranoside (TBGF);
CAS Number	10310-32-4 ;
PubChem CID	196122;
ChemSpider	169970 ;
UNII	Z7N0Y673NU;
ChEMBL	ChEMBL1446743 ;
CompTox Dashboard (EPA)	DTXSID7023697 ;
ECHA InfoCard	100.030.612
Chemical and physical data
Formula	C29H34O6
Molar mass	478.585 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1[C@@H]([C@H]([C@H](O1)[C@@H](COCc2ccccc2)OCc3ccccc3)OCc4ccccc4)O;
	InChI InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25-,26-,27-,28-,29?/m1/s1 ; Key:ULLNJSBQMBKOJH-VIVFLBMVSA-N ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Tribenoside (Glyvenol) is a vasoprotective drug used to treat hemorrhoids.^[1] It has mild anti-inflammatory, analgesic, and wound healing properties.^[2] Tribenoside stimulates laminin α5 production and laminin-332 deposition to help repair the basement membrane during the wound healing process.^[3] It is a mixture of the α- and β-anomers.^{[citation needed]}

Tribenoside has been shown to induce drug hypersensitivity syndrome in association with CMV reactivation.^[4]

References

^ Lorenc Z, Gökçe Ö (2016). "Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence". Eur Rev Med Pharmacol Sci. 20 (12): 2742–51. PMID 27383331.
^ Jaques R (1977). "The pharmacological activity of tribenoside". Pharmacology. 15 (5): 445–60. doi:10.1159/000136721. PMID 578928.
^ Kikkawa Y, Takaki S, Matsuda Y, Okabe K, Taniguchi M, Oomachi K, Samejima T, Katagiri F, Hozumi K, Nomizu M (2010). "The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells". Biol Pharm Bull. 33 (2): 307–10. doi:10.1248/bpb.33.307. PMID 20118558.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Hashizume H, Takigawa M (2005). "Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells". Acta Derm. Venereol. 85 (1): 47–50. doi:10.1080/00015550410024094. PMID 15848991.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[pmid27383331-1] Lorenc Z, Gökçe Ö (2016). "Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence". Eur Rev Med Pharmacol Sci. 20 (12): 2742–51. PMID 27383331.

[pmid578928-2] Jaques R (1977). "The pharmacological activity of tribenoside". Pharmacology. 15 (5): 445–60. doi:10.1159/000136721. PMID 578928.

[pmid20118558-3] Kikkawa Y, Takaki S, Matsuda Y, Okabe K, Taniguchi M, Oomachi K, Samejima T, Katagiri F, Hozumi K, Nomizu M (2010). "The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells". Biol Pharm Bull. 33 (2): 307–10. doi:10.1248/bpb.33.307. PMID 20118558.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[pmid15848991-4] Hashizume H, Takigawa M (2005). "Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells". Acta Derm. Venereol. 85 (1): 47–50. doi:10.1080/00015550410024094. PMID 15848991.

[1]